Company
CNSX:MSET
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, covering multiple drug development programs.
65 stories · page 2 of 4
The new platform leverages the company's unique platform technology, altering the pharmacokinetics profile of the active pharmaceutical ingredient and can deliver improved central nervous system (CNS) penetration of the medicines, the compa
Mindset Pharma CEO James Lanthier said the collaboration would profile and build the company’s understanding of the observed superiority of its lead asset MSP-1014 to psilocybin at the molecular level
“This is a key step towards continued growth for Mindset and our developing pipeline of drug candidates,” Mindset Pharma CEO James Lanthier said
“We have selected an expert contract research organization, Clerkenwell Health, to lead the initial scientific discussions with the regulators in the UK as we start to pull together our clinical plans,” said Mindset CEO James Lanthier
"As we get more human clinical data from first-generation psychedelic drugs, we will unravel how different patients respond to different psychedelic therapies,” the company’s CEO James Lanthier said
In preclinical studies, Mindset's lead drug candidate MSP-1014, believed to be suited to address treatment-resistant depression and end-of-life cancer angst has showed improved efficacy and safety profile compared to first-generation psiloc
Specifically, Mindset has further developed standard pharmacokinetics and drug discrimination data and protocols across LSD, psilocybin, 5-MeO-DMT, and now psilocin
Randall is a renowned scientist with industry research experience with Eisai, GSK, and Merck and has worked in the USA, UK, China, and Japan
To better understand potential pro-cognitive benefits across a range of sub-hallucinogenic doses, Mindset will initiate a series of in vivo proof of concept studies, which will measure motivation and attention
Archive
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
The company said it continues to receive interest from potential partners for its wider portfolio of differentiated next-generation drug candidates
As reported by Mindset, the tie-up consists of a US$5 million upfront cash payment and operational support to develop two 2nd generation psychedelic families in Mindset's pipeline through phase 1a and phase 1b trials
MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, the company said
As the company enters 2022, it is progressing with investigational new drug-enabling studies for its lead candidate MSP-1014
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Chief Scientific Officer Joseph Araujo said 'such compounds may be optimal for indications in which a long-term, micro-dosing, paradigm is advantageous, such as ADHD or Alzheimer’s disease'
The company saw early on that there would be a wave of interest in using psychedelic drugs as medication, but that ultimately there would be even more interest in next-generation drugs delivering greater benefits as medication with full pat
Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues
In focus will be the pre-clinical benchmarking data for Mindset's optimized psilocybin analog MSP-1014 compared to first-generation psychedelic compounds
The research group wrote that Toronto-based Mindset is “pioneering the next generation of psychedelic-enhanced therapies"
